SK Bioscience Stock Outlook 2026: A Vaccine Maker's Pivot from COVID Windfall to CDMO Recurring Revenue
SK Bioscience (KRX: 302440) 2026 stock analysis: own vaccine pipeline (pneumococcal, shingles, flu), the pivot from one-off COVID manufacturing into recurring CDMO and cell-and-gene therapy contract production, German acquisition and glocalization strategy, plus the post-COVID earnings cliff and R&D-burn risks.
SK Bioscience 302440 vaccines